192 related articles for article (PubMed ID: 24580550)
21. Search for epithelial-specific mRNAs in peripheral blood of patients with colon cancer by RT-PCR.
Solmi R; De Sanctis P; Zucchini C; Ugolini G; Rosati G; Del Governatore M; Coppola D; Yeatman TJ; Lenzi L; Caira A; Zanotti S; Taffurelli M; Carinci P; Valvassori L; Strippoli P
Int J Oncol; 2004 Oct; 25(4):1049-56. PubMed ID: 15375555
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
23. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening.
Koga Y; Yasunaga M; Takahashi A; Kuroda J; Moriya Y; Akasu T; Fujita S; Yamamoto S; Baba H; Matsumura Y
Cancer Prev Res (Phila); 2010 Nov; 3(11):1435-42. PubMed ID: 20959518
[TBL] [Abstract][Full Text] [Related]
25. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia.
Kato J; Morikawa T; Kuriyama M; Yamaji Y; Wada R; Mitsushima T; Yamamoto K
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1341-6. PubMed ID: 19426835
[TBL] [Abstract][Full Text] [Related]
26. Performance improvements of stool-based screening tests.
van Dam L; Kuipers EJ; van Leerdam ME
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
[TBL] [Abstract][Full Text] [Related]
27. Update: non-invasive screening test for colon cancer; colonoscopy refined. These new findings may improve accuracy and subsequent treatment for colon cancer; some experts disagree.
Duke Med Health News; 2011 Jan; 17(1):4. PubMed ID: 21313728
[No Abstract] [Full Text] [Related]
28. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
Webendörfer S; Riemann JF
Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
[TBL] [Abstract][Full Text] [Related]
29. Colon cancer screening strategies.
Agrawal J; Syngal S
Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
[TBL] [Abstract][Full Text] [Related]
30. Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment.
Ahmed FE
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2003 Nov; 21(2):65-131. PubMed ID: 15845222
[TBL] [Abstract][Full Text] [Related]
31. [Down-regulative expression of microRNAs cluster in human colon tumorigenesis].
Ba Y; Cai X; Chen X; Yin Y; Zhang Y; Zhang CY
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1683-6. PubMed ID: 19024538
[TBL] [Abstract][Full Text] [Related]
32. Molecular tests for colorectal cancer screening.
Bosch LJ; Carvalho B; Fijneman RJ; Jimenez CR; Pinedo HM; van Engeland M; Meijer GA
Clin Colorectal Cancer; 2011 Mar; 10(1):8-23. PubMed ID: 21609931
[TBL] [Abstract][Full Text] [Related]
33. Noninvasive testing for colorectal cancer: a review.
Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
[TBL] [Abstract][Full Text] [Related]
34. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
35. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China.
Zhang J; Yang S; Xie Y; Chen X; Zhao Y; He D; Li J
Cancer Epidemiol; 2012 Feb; 36(1):73-7. PubMed ID: 21621497
[TBL] [Abstract][Full Text] [Related]
36. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
37. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps.
Wu CW; Ng SS; Dong YJ; Ng SC; Leung WW; Lee CW; Wong YN; Chan FK; Yu J; Sung JJ
Gut; 2012 May; 61(5):739-45. PubMed ID: 21930727
[TBL] [Abstract][Full Text] [Related]
38. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates.
Berger BM; Ahlquist DA
Pathology; 2012 Feb; 44(2):80-8. PubMed ID: 22198259
[TBL] [Abstract][Full Text] [Related]
39. Colon cancer secreted protein-2 (CCSP-2), a novel candidate serological marker of colon neoplasia.
Xin B; Platzer P; Fink SP; Reese L; Nosrati A; Willson JK; Wilson K; Markowitz S
Oncogene; 2005 Jan; 24(4):724-31. PubMed ID: 15580307
[TBL] [Abstract][Full Text] [Related]
40. Application of the fecal microRNA test to the residuum from the fecal occult blood test.
Yamazaki N; Koga Y; Yamamoto S; Kakugawa Y; Otake Y; Hayashi R; Saito N; Matsumura Y
Jpn J Clin Oncol; 2013 Jul; 43(7):726-33. PubMed ID: 23677957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
